Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14918536 | 0.80 | DPP4 (0.44) | DPP4GPR119HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL14918065 | 0.79 | DPP4 (0.43) | DPP4GPR119HRH4HRH3 | |
| SCHEMBL23083016 | 0.76 | DPP4 (0.50) | DPP4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL387980 | 0.72 | CHRNB2 (0.45) | DPP4GPR119 | |
| SCHEMBL14918137 | 0.72 | DPP4 (0.41) | DPP4HRH4 | |
| SCHEMBL14918640 | 0.71 | DPP4 (0.42) | DPP4HRH4GLS | |
| SCHEMBL387876 | 0.71 | GPR119 (0.71) | MAPK8MAPK10GPR119 | |
| SCHEMBL14917742 | 0.70 | DPP4 (0.42) | DPP4HRH3 | |
| SCHEMBL16011093 | 0.70 | DPP4 (0.39) | DPP4HRH3 | |
| SCHEMBL14918167 | 0.70 | DPP4 (0.39) | DPP4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | DPP4 25/4885MAPK8 1710/4885MAPK10 2532/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | DPP4 25/4885MAPK8 1710/4885MAPK10 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.